Trial Profile
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics; Antineoplastics
- Indications Haematological malignancies; Solid tumours
- Focus Therapeutic Use
- Acronyms KEYNOTE-587; MK-3475-587/KEYNOTE-587
- Sponsors Merck Sharp & Dohme Corp.
- 21 Dec 2023 The given protocol has been amended as above- 1) Planned number of patients has been changed from 2300 to 3500. 2) Number of treatment arms has been changed from 5 to 9.
- 21 Dec 2023 Planned number of patients changed from 2300 to 3500.
- 17 Jul 2023 This trial has been completed in Greece, according to European Clinical Trials Database record.